An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.
from Reuters: Health https://ift.tt/2tB4na2
No comments:
Post a Comment